Association of PON1 gene promoter DNA methylation with the risk of Clopidogrel resistance in patients with coronary artery disease
- PMID: 30891852
- PMCID: PMC6595294
- DOI: 10.1002/jcla.22867
Association of PON1 gene promoter DNA methylation with the risk of Clopidogrel resistance in patients with coronary artery disease
Abstract
Background and aims: The failure of therapeutic response to clopidogrel in platelet inhibition, which is called clopidogrel resistance (CR), is more likely to cause cardiovascular events. We aimed to study the contribution of promoter DNA methylation of paraoxonase 1 (PON1) to the risk of clopidogrel poor response.
Methods: Through VerifyNow P2Y12 assay, patient' platelet functions were measured. Among 57 non-CR and 49 CR patients, the levels of DNA methylation in four CpG dinucleotides on the PON1 promoter were tested using bisulfite pyrosequencing technology. Besides, the relative expression of PON1 mRNA was analyzed by quantitative real-time PCR. Logistic regression was applied to investigate the interaction of PON1 methylation and clinical factors in CR.
Results: In the subgroup with dyslipidemia, we discovered that higher CpG4 levels of the PON1 promoter indicated a poorer clopidogrel response (cases versus controls (%): 51.500 ± 14.742 vs 43.308 ± 10.891, P = 0.036), and the PON1 mRNA expression was reduced in CR patients. Additionally, the logistic regression indicated that higher level of albumin and the index of ALT were related to a lower risk of CR, and the index of AST as well as the quantity of stent may be positively associated with CR.
Conclusions: The DNA methylation of CpG4 in the PON1 promoter would lead to a low expression of PON1 mRNA, which might induce clopidogrel resistance in the patients with dyslipidemia, and the number of stents might be a risk for CR.
Keywords: PON1; DNA methylation; clopidogrel resistance; coronary artery disease.
© 2019 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc.
Figures



Similar articles
-
Association of GCK gene DNA methylation with the risk of clopidogrel resistance in acute coronary syndrome patients.J Clin Lab Anal. 2020 Feb;34(2):e23040. doi: 10.1002/jcla.23040. Epub 2019 Oct 11. J Clin Lab Anal. 2020. PMID: 31605429 Free PMC article.
-
Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients.Biomed Res Int. 2014;2014:450814. doi: 10.1155/2014/450814. Epub 2014 Mar 18. Biomed Res Int. 2014. PMID: 24745016 Free PMC article.
-
Effects of PON1 Gene Promoter DNA Methylation and Genetic Variations on the Clinical Outcomes of Dual Antiplatelet Therapy for Patients Undergoing Percutaneous Coronary Intervention.Clin Pharmacokinet. 2018 Jul;57(7):817-829. doi: 10.1007/s40262-017-0595-4. Clin Pharmacokinet. 2018. PMID: 28875477
-
Pharmacogenomics of clopidogrel: evidence and perspectives.Thromb Res. 2011 Oct;128(4):307-16. doi: 10.1016/j.thromres.2011.04.010. Epub 2011 May 18. Thromb Res. 2011. PMID: 21592545 Review.
-
Contemporary use of clopidogrel in patients with coronary artery disease.Curr Cardiol Rep. 2007 Jul;9(4):257-63. doi: 10.1007/BF02938373. Curr Cardiol Rep. 2007. PMID: 17601391 Review.
Cited by
-
A male-specific association between AGTR1 hypermethylation and coronary heart disease.Bosn J Basic Med Sci. 2020 Feb 5;20(1):31-36. doi: 10.17305/bjbms.2019.4321. Bosn J Basic Med Sci. 2020. PMID: 31538912 Free PMC article.
-
The DNAm levels of CREB5 (cg11301281) were associated with clopidogrel resistance.J Clin Lab Anal. 2022 Oct;36(10):e24690. doi: 10.1002/jcla.24690. Epub 2022 Sep 10. J Clin Lab Anal. 2022. PMID: 36087301 Free PMC article.
-
Association of APOE (rs429358 and rs7412) and PON1 (Q192R and L55M) Variants with Myocardial Infarction in the Pashtun Ethnic Population of Khyber Pakhtunkhwa, Pakistan.Genes (Basel). 2023 Mar 10;14(3):687. doi: 10.3390/genes14030687. Genes (Basel). 2023. PMID: 36980959 Free PMC article.
-
Safety and efficacy of nivolumab compared with other regimens in patients with melanoma: A network meta-analysis.Medicine (Baltimore). 2022 Sep 2;101(35):e29390. doi: 10.1097/MD.0000000000029390. Medicine (Baltimore). 2022. PMID: 36107612 Free PMC article.
-
Association of GCK gene DNA methylation with the risk of clopidogrel resistance in acute coronary syndrome patients.J Clin Lab Anal. 2020 Feb;34(2):e23040. doi: 10.1002/jcla.23040. Epub 2019 Oct 11. J Clin Lab Anal. 2020. PMID: 31605429 Free PMC article.
References
-
- Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet‐mediated atherothrombosis. Thromb Haemost. 2009;102(2):248‐257. - PubMed
-
- Jneid H, Addison D, Bhatt DL, et al. 2017 AHA/ACC clinical performance and quality measures for adults with ST‐elevation and Non‐ST‐elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2017;70(16):2048‐2090. - PubMed
-
- Udell JA, Bonaca MP, Collet JP, et al. Long‐term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta‐analysis of randomized trials. Eur Heart J. 2016;37(4):390‐399. - PubMed
-
- Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45(8):1157‐1164. - PubMed
-
- Hochholzer W, Trenk D, Bestehorn HP, et al. Impact of the degree of peri‐interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006;48(9):1742‐1750. - PubMed
MeSH terms
Substances
Grants and funding
- LY19H310002, LY19H020003/Zhejiang Provincial Natural Science Foundation of China
- 2017KY574/the funding of the Plan of Science and Technology on Medicine and Health in Zhejiang Province
- PPXK2018-01/Ningbo Health Branding Subject Fund
- LY19H310002/Zhejiang Provincial Natural Science Foundation of China
- LY19H020003/Zhejiang Provincial Natural Science Foundation of China
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous